Prognostic proof and possible therapeutic mechanisms of herbal medicine in patients with metastatic lung and colon cancer

Integrative Cancer Therapies

Volumn 10, Issue 3, 2011, Pages

  Baak, Jan P A A ^a,b   Gyllenhaal, Charlotte ^c   Liu, Luming ^b,c   Guo, Huiru ^d   Block, Keith I ^e  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e Block Center for Integrative Cancer Treatment   (United States)

Author keywords

cancer; colon; herbal treatment; lung; prognosis; therapeutic mechanism

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GEFITINIB; HERBACEOUS AGENT; PLATINUM; VITAMIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EUROPEAN UNION; HEALTH CARE COST; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; INTEGRATIVE MEDICINE; LIFESTYLE MODIFICATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICINE; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; WESTERN MEDICINE;

ANIMALS; COLONIC NEOPLASMS; DRUGS, CHINESE HERBAL; HUMANS; LUNG NEOPLASMS; MEDICINE, CHINESE TRADITIONAL; NEOPLASM METASTASIS; PHYTOTHERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84855397828     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411421172     Document Type: Review

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 ; 61: 69-90
2. Jin F, Devesa SS, Chow WH, et al. Cancer incidence trends in urban Shanghai, 1972-1994: an update. Int J Cancer. 1999 ; 83: 435-440 (Pubitemid 29489855)
3. Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005 ; 14: 243-250 (Pubitemid 40165308)
4. Yang L, Li LD, Chen YD, et al. Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi. 2006 ; 28: 438-440
5. McCulloch M, See C, Shu X, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006 ; 24: 419-430 (Pubitemid 46655594)
6. Molassiotis A, Panteli V, Patiraki E, et al. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract. 2006 ; 12: 34-39 (Pubitemid 43056766)
7. Lam YC, Cheng CW, Peng H, Law CK, Huang X, Bian Z. Cancer patients' attitudes towards Chinese medicine: a Hong Kong survey. Chin Med. 2009 ; 4: 25
8. Guo HR, Liu JX, Xu L, Madebo T, Baak JP. Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined target- and chemotherapy. Integr Cancer Ther. 2011 ; 10: 127-137
9. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32004L0024:EN:HTML, Directive 2001/83/EC on the Community code relating to medicinal products for human use http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and- procedural-guideline/2009/10/WC500004481.pdf.
10. MHRA. Traditional herbal medicines registration scheme. http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicines/ PlacingaherbalmedicineontheUKmarket/ TraditionalHerbalMedicinesRegistrationScheme. Accessed August 13, 2011.
11. Olson JS Baltimore, MD: Johns Hopkins University Press ; 2002: 145-170.
12. Keppel HJ, Kopsky DJ Now really: science. Deventer, the Netherlands: ANKH ; 55-70.
13. Liu JX, Shi ZM, Li HG. The clinical research of the principle of nourishing yin and promoting fluid production, benefiting qi and warming yang in treating advanced primary lung adenocarcinoma. J Tradit Chin Med. 1995 ; 36: 155-158
14. McCulloch M, Broffman M, van der Laan M, et al Integr Cancer Ther.
15. McCulloch M, Broffman M, van der Laan M, et al Integr Cancer Ther.
16. Ouyang H, Wang P, Meng Z, et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas. 2011 ; 40: 120-125
17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 ; 346: 92-98 (Pubitemid 34438899)
18. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 ; 361: 947-957
19. Li J, Bao Y, Lam W, et al. Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice. Immunopharmacol Immunotoxicol. 2008 ; 30: 771-782
20. Zhang Y, Hu G, Lin HC, et al. Radix Astragali extract promotes angiogenesis involving vascular endothelial growth factor receptor-related phosphatidylinositol 3-kinase/Akt-dependent pathway in human endothelial cells. Phytother Res. 2009 ; 23: 1205-1213
21. Chakraborty S, Ganti AK, Marr A, Batra SK. Lung cancer in women: role of estrogens. Expert Rev Respir Med. 2010 ; 4: 509-518
22. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. 2005 ; 11: 7280-7287 (Pubitemid 41507685)
23. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 ; 15: 5359-5368
24. Olivo-Marston SE, Mechanic LE, Mollerup S, et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis. 2010 ; 31: 1778-1786
25. Marquez-Garban DC, Mah V, Alavi M, et al. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011 ; 76: 910-920
26. Ogunleye AA, Holmes MD. Physical activity and breast cancer survival. Breast Cancer Res. 2009 ; 11: 106
27. Byers T, Sedjo RL. Does intentional weight loss reduce cancer risk?. Diabetes Obes Metab. :
28. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008 ; 8: 915-928
29. Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007 ; 98: 1424-1430 (Pubitemid 47243535)
30. Øvestad IT, Gudlaugsson E, Skaland I, et al. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol. 2010 ; 23: 1231-1240
31. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, Maione P. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2010 ; 19: 631-639
32. Rensing KL, Houttuijn Bloemendaal FM, Weijers EM, et al. Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis?. Diabetologia. 2010 ; 53: 966-970
33. Harboe E, Tjensvoll AB, Vefring HK, Gøransson LG, Kvaløy JT, Omdal R. Fatigue in primary Sjögren's syndrome: a link to sickness behaviour in animals?. Brain Behav Immun. 2009 ; 23: 1104-1108
34. Norheim KB, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology. 2011 ; 50: 1009-1018
35. Jehn CF, Kühnhardt D, Bartholomae A, et al. Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther. 2010 ; 9: 270-275
36. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998 ; 128: 127-137 (Pubitemid 28053135)
37. Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, et al. The value of serum S-100beta and interleukins as tumor markers in advanced melanoma. Melanoma Res. 2000 ; 10: 237-241
38. Breuninger LM, Dempsey WL, Uhl J, Murasko DM. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 1993 ; 69: 205-214 (Pubitemid 23319389)
39. Papanicolaou DA, Petrides JS, Tsigos C, et al. Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 1996 ; 271: E601 - E605
40. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993 ; 77: 1690-1694 (Pubitemid 24000936)
41. Besedovsky HO, Del Rey A. Immune-neuro-endocrine interaction: facts and hypotheses. Endocr Rev. 1996 ; 17: 64-102
42. van der Greef J, van Wietmarschen H, Schroën J, Wang M, Hankemeier T, Xu G. Systems biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. Planta Med. 2010 ; 76: 2036-2047
43. Lim LC, Lu JH, Linn YC, et al. Prospective study evaluating use of traditional Chinese medicine to treat refractory cytopenia(s) in chronic hematological disorders: safety, efficacy and impact on quality of life. Blood. 2010 ; 116: 4764
44. Chan KKL, Yao TJ, Jones B, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol.:
45. Linn YC, Lu J, Lim LC, et al. Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopenic marrow diseases: a phase I/II clinical study. Complement Ther Clin Pract. 2011 ; 17: 152-156
46. Zhang M, Liu X, Li J, et al. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007 ; (2). CD004921
47. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 ; 363: 733-742
48. Guo H, Liu L, Baak J Int Cancer Ther.